RO.CH

325.6

+0.74%↑

NOVN.CH

113.89

+0.11%↑

SDZ.CH

65.52

+3.97%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

74.8

+0.94%↑

RO.CH

325.6

+0.74%↑

NOVN.CH

113.89

+0.11%↑

SDZ.CH

65.52

+3.97%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

74.8

+0.94%↑

RO.CH

325.6

+0.74%↑

NOVN.CH

113.89

+0.11%↑

SDZ.CH

65.52

+3.97%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

74.8

+0.94%↑

RO.CH

325.6

+0.74%↑

NOVN.CH

113.89

+0.11%↑

SDZ.CH

65.52

+3.97%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

74.8

+0.94%↑

RO.CH

325.6

+0.74%↑

NOVN.CH

113.89

+0.11%↑

SDZ.CH

65.52

+3.97%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

74.8

+0.94%↑

Начало・Списък с акции・Lonza Group AG

Lonza Group AG

Затворен

СекторЗдравеопазване

493.4 3.09

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

478.65

Максимум

494.2

Ключови измерители
By Trading Economics
Приходи	57M 483M
Продажби	-621M 3B
P/E Средно за сектора	37.585 67.147
Дивидентна доходност	1.04
Марж на печалбата	16.345
Служители	20,000
EBITDA	-181M 822M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+37.73% upside

Дивиденти
By Dow Jones
Дивидентна доходност Средно за сектора	1.04% 2.36%
Следващи печалби	22.07.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-4.6B 34B
Предишно отваряне	490.31
Предишно затваряне	493.4

Настроения в новините

By Acuity

14%

86%

24 / 347 Класиране в Healthcare

Lonza Group AG Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

6.03.2026 г., 17:44 ч. UTC

Придобивния, сливания и поглъщания

Lonza to Offload Majority Stake in Capsule Business to Lone Star in $2.2 Billion Deal

28.01.2026 г., 06:15 ч. UTC

Печалби

Lonza Sales Grow on New Contract Momentum

23.07.2025 г., 08:30 ч. UTC

Печалби

Значими двигатели на пазара

Lonza Shares Rise After Outlook Lift for Core Business

9.03.2026 г., 10:34 ч. UTC

Пазарно говорене

Lonza Might Disappoint Investors With Capsule Business Valuation -- Market Talk

6.03.2026 г., 17:12 ч. UTC

Придобивния, сливания и поглъщания

Correct: Lonza to Sell Capsules & Health Ingredients Business to Lone Star Funds

6.03.2026 г., 17:10 ч. UTC

Придобивния, сливания и поглъщания

Lonza: Total Undiscounted Proceeds Expected to Be at or Above CHF3B

6.03.2026 г., 17:09 ч. UTC

Придобивния, сливания и поглъщания

Lonza to Retain 40% Stake in CHI

6.03.2026 г., 17:08 ч. UTC

Придобивния, сливания и поглъщания

Lonza Will Receive Upfront Proceeds of CHF1.7B

6.03.2026 г., 17:07 ч. UTC

Придобивния, сливания и поглъщания

Lonza: Transaction Expected to Close in 2H

6.03.2026 г., 17:07 ч. UTC

Придобивния, сливания и поглъщания

Lonza: This Is for Enterprise Value of CHF2.3B at Closing

6.03.2026 г., 17:06 ч. UTC

Придобивния, сливания и поглъщания

Lonza to Sell Capsules & Health Ingredients Business Lone Star Funds

28.01.2026 г., 12:04 ч. UTC

Пазарно говорене

Печалби

Lonza Results Show a Company in Good Shape -- Market Talk

28.01.2026 г., 05:35 ч. UTC

Печалби

Lonza Anticipates 2026 Core EBITDA Margin to Reach Level Above 32%

28.01.2026 г., 05:34 ч. UTC

Печалби

Lonza Anticipates 2026 Sales Growth of 11-12% at CER

28.01.2026 г., 05:33 ч. UTC

Печалби

Lonza Issues 2026 View

28.01.2026 г., 05:32 ч. UTC

Печалби

Lonza 2025 Core Ebitda Margin 31.6%

28.01.2026 г., 05:32 ч. UTC

Печалби

Analysts Saw Lonza 2025 Core Ebitda at CHF2.27B

28.01.2026 г., 05:32 ч. UTC

Печалби

Lonza 2025 Core Ebitda CHF2.06B

28.01.2026 г., 05:30 ч. UTC

Печалби

Analysts Saw Lonza 2025 Sales at CHF7.54B

28.01.2026 г., 05:30 ч. UTC

Печалби

Lonza 2025 Sales CHF6.53B

27.10.2025 г., 08:24 ч. UTC

Пазарно говорене

Lonza on Track to Meet Long-Term Goals -- Market Talk

23.10.2025 г., 10:53 ч. UTC

Пазарно говорене

Печалби

Lonza Set to Recover as Contracts Flow in -- Market Talk

23.07.2025 г., 08:00 ч. UTC

Пазарно говорене

Печалби

Lonza Nudges Up Full-Year Guidance for Core Business After Good Results -- Market Talk

23.07.2025 г., 04:44 ч. UTC

Печалби

Lonza 1H Sales Grew 19% at Constant Currency

23.07.2025 г., 04:43 ч. UTC

Печалби

Lonza 1H Core Ebitda Margin 29.6%

23.07.2025 г., 04:43 ч. UTC

Печалби

Lonza: Margins Will Be Only Minimally Affected

23.07.2025 г., 04:42 ч. UTC

Печалби

Lonza Expects FX Headwind of -2.5% to -3.5% on 2025 Sales and Core Ebitda

23.07.2025 г., 04:42 ч. UTC

Печалби

Lonza: This Is Mainly From Weakening of U.S. Dollar

23.07.2025 г., 04:38 ч. UTC

Печалби

Lonza 1H Net Pft CHF426M

23.07.2025 г., 04:37 ч. UTC

Печалби

Lonza Backs 2025 View for CHI Business

Сравнение с други в отрасъла

Ценова промяна

Lonza Group AG Прогноза

Ценова цел

By TipRanks

37.73% нагоре

12-месечна прогноза

Среден 660 CHF 37.73%

Висок 670 CHF

Нисък 630 CHF

Според 4 анализатори от Wall Street, предложили 12-месечна ценова цел за Lonza Group AG през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

4 ratings

Купи

Задържане

Продай

Според 4 анализатори, дали борсови рейтинги на Lonza Group AG през последните 3 месеца.

Настроение

By Acuity

24 / 347 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Lonza Group AG

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. This segment also supports customers across various aspects of design, development, and manufacturing, including particle engineering and drug product packaging. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies; offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment also provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.